SCHEMBL20802175

SCHEMBL20802175

COc1cc(-c2oc3cc(O)cc(O)c3c(=O)c2OC[C@@H](OC2OC(CO)C(O)C(O)C2O)C(O)C(O)C(O)CO)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHX2 P34913 4/20 0.71
▸ MMP9 P14780 1/20 0.62
▸ MEN1 O00255 1/20 0.61
▸ KMT2A Q03164 1/20 0.61
▸ P4HB P07237 5/20 0.58
▸ AKR1B1 P15121 4/20 0.58
▸ KDM4E B2RXH2 4/20 0.58
▸ GAA P10253 4/20 0.58
▸ MAPT P10636 4/20 0.58
▸ POLB P06746 3/20 0.58
▸ CA12 O43570 2/20 0.58
▸ CA2 P00918 2/20 0.58
▸ CA4 P22748 2/20 0.58
▸ CA7 P43166 2/20 0.58
▸ LMNA P02545 2/20 0.58
▸ ADRA2C P18825 1/20 0.58
▸ NOX4 Q9NPH5 1/20 0.58
▸ KDM1A O60341 1/20 0.58
▸ SLCO2B1 O94956 1/20 0.58
▸ ALPL P05186 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20802116 0.92 P4HB (0.62) EPHX2MMP9P4HBAKR1B1KDM4E
SCHEMBL20802113 0.92 GAA (0.69) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL20802114 0.85 P4HB (0.66) EPHX2P4HBAKR1B1KDM4EGAA
SCHEMBL20802174 0.84 KDM4E (0.64) EPHX2P4HBAKR1B1KDM4EGAA
SCHEMBL25223513 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL13926870 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL2025447 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL13926793 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL31238537 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB
SCHEMBL28767123 0.84 EPHX2 (1.00) EPHX2MMP9MEN1KMT2AP4HB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2020-09-08 — — US disclosed
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2019-03-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10765128-B2 Composition for prevention or treatment of metabolic syndrome or for antioxidation containing black bean leaf extracts and flavonol glysosides isolated therefrom as active ingredients GPX1, GSTP1, GSS EPHX2 3943/4885MMP9 573/4885MEN1 4497/4885
US-20190075823-A1 COMPOSITION FOR PREVENTION OR TREATMENT OF METABOLIC SYNDROME OR FOR ANTIOXIDATION CONTAINING BLACK BEAN LEAF EXTRACTS AND FLAVONOL GLYSOSIDES ISOLATED THEREFROM AS ACTIVE INGREDIENTS GPX1, GSTP1, PON1 EPHX2 2927/4885MMP9 801/4885MEN1 4024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback